Skip to main content
. 2021 Jun 15;6(4):100171. doi: 10.1016/j.esmoop.2021.100171

Figure 3.

Figure 3

mPPGL patients treated with 177Lu the mPFS was nr (right).

The mOS of this population was 143.5 months (95% CI 143.5-146.2 months) (left).

CI, confidence interval; mOS, median overall survival; mPFS, median progression-free survival; mPPGL, metastatic pheochromocytoma and paraganglioma; nr, not reached.